Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
NCT ID: NCT01819064
Last Updated: 2023-04-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2013-02-28
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the present study is to measure the heart rate after doses of atropine in neonates and infants who receive less than 0.1 mg.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation
NCT01595399
Dopamine Versus Norepinephrine Under General Anesthesia
NCT04536194
Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation
NCT05738148
EEG to Monitor Propofol Anesthetic Depth in Infants and Toddlers
NCT05701748
Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation
NCT02040909
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All children will be fasted according to institutional guidelines and unpremedicated. After arriving in the operating room, EKG, pulse oximeter and blood pressure monitors will be applied (Datex-Ohmeda Aisys).
Anesthesia will be induced with 66% N2O in O2 and 8% sevoflurane. Respiration will be supported by a properly sized face mask through which he/she is allowed to breath spontaneously. Respiration will continue spontaneously through a facemask at 2 MAC sevoflurane in 66% N2O.
All children will be positioned supine, warmed with a forced air warmer and given 20 ml/kg IV balanced salt solution over 30 minutes after the IV has been established. The end-tidal pCO2 will maintained 35-45 mmHg and oxygen saturation \>96%.
After a 22 or 24G IV cannula is inserted, 0.005 mg/kg atropine will be administered intravenously over 5 seconds through a fast-flowing IV and followed by 5 ml of normal saline to flush it in through the IV deadspace. The study (ECG recording) period will extend from 30 seconds before atropine administration to 5 minutes after injection. During this time the heart rate and rhythm (through lead II) will be monitored and recorded continuously using an analogue interface system. EKG will be recorded on paper continuously for the 330 seconds of the study.
The recording will be analyzed for the heart rate (based on the R-R interval) and arrhythmias by a physician blinded to the study. Blinding means that the individual is unaware of the hypothesis of the study and what medication was administered to account for any changes in heart rate. Bradycardia is defined as a 20% reduction from baseline heart rate while tachycardia is a heart rate \> 160 beats/minute(6). Any heart rate \< 100/minute will be considered a bradycardia in this age group. Arrhythmia is any disorder of rhythm or rate observed. These will be summarized for each child.
All heart rate responses will be recorded and reviewed. The time to record the heart rate after atropine, which will occur before surgery, will add less than 5 additional minutes to the anesthetic since it will overlap the time taken for other surgical preparatory events.
The blood pressure will be monitored non-invasively immediately before receiving atropine and at one and five minutes after it is given.
The primary outcome is the incidence of bradycardia during the first 5 minutes after atropine will be determined by reviewing the electrocardiogram. All continuous data will be reported as means +/- standard deviation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infants and children less than 15Kg.
This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
Atropine
intravenous atropine affect on heart rate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atropine
intravenous atropine affect on heart rate
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Weight : less than the 95th percentile for age and height ( no more than 15kg )
3. ASA classification : I-II
4. Meets the hospital and department of anesthesiology guidelines with respect to peri-operative care
Exclusion Criteria
2. Any condition predisposing to arrhythmia
3. Any medication known to influence the heart rate
4. Child taking anti-cholinergic medication routinely
5. The use of succinylcholine anticipated (will cause bradycardia)
6. Rapid sequence intubation is required (due to aspiration risk)
7. Known difficult airway (may be difficult to bag mask ventilate)
1 Day
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
State University of New York at Buffalo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jerrold Lerman
Clinical Professor of Anesthesiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerrold Lerman, MD FRCPC
Role: PRINCIPAL_INVESTIGATOR
SUNY at Buffalo, Women and Children's Hospital of Buffalo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women and Children's Hospital of Buffalo
Buffalo, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Eisa L, Passi Y, Lerman J, Raczka M, Heard C. Do small doses of atropine (<0.1 mg) cause bradycardia in young children? Arch Dis Child. 2015 Jul;100(7):684-8. doi: 10.1136/archdischild-2014-307868. Epub 2015 Mar 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Atropine in infants
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.